Advocates for medicinal and retail marijuana are quick to list the benefits of legalization. Increased jobs, tax money, medical benefits, and “safe,” “healthy,” and “organic” marketing. They use “cannabis” and “marijuana” interchangeably, without distinguishing between distinct types of cannabis that have varied effects on the mind and body.
Cannabis- Clinical Trial Examination
Many who voted for legalization assumed they were talking about marijuana from the 1960s to the 1980s when the THC level was less than 2%. Without clear government standards or laws, the cannabis sector has developed marijuana strains and concentrated marijuana products with increasing quantities of THC, the psychoactive component that promotes addiction. The stronger a drug, the greater the likelihood of addiction and continued use.
A pharmaceutical company developing remedies for central nervous system illnesses recently revealed it has started preparing an Investigational New Drug (IND) Application with the FDA for its Phase IIb clinical trial of cannabis-derived medication to treat Tourette syndrome (TS). The IND submission may help launch a new U.S. Phase IIb trial location.
The medicine is being developed under the accelerated regulatory path of Section 505 (b)(2) application to enhance FDA-approved natural and synthetic cannabinoids to build therapeutics that potentiate cannabis effects and target CNS receptors.
After a successful Phase IIa trial, in which TS patients’ tic symptoms were reduced by 21%, the company is moving on to the next phase. The trial’s primary objective is to quantify tic severity change as a continuous endpoint at weeks 12 and 26 of the double-blind phase. The trial will examine the absolute and relative frequency of major adverse events for the total population and individually for the medication candidate and placebo groups.
Also read-Cogent and Green Check Verified collaborates to provide FinTech solutions to cannabis businesses
Are Topicals Often Mislabeled?
Mislabeling of topical cannabinoids is common, a study finds. 18% of topical cannabis products were mislabeled (containing 10% less CBD than stated), while 58% were mislabeled (containing more than 10% more CBD than stated).24% of goods were labeled correctly. 35% of the assessed goods contained THC, all less than 0.3%. 47% of items weren’t FDA-approved.
The latest research indicates that “better regulatory monitoring of cannabis and hemp products is essential to assure quality assurance, avoid deceptive health claims, and potentially prevent undesired drug effects among users.” To find out if topical THC can make you feel high or show up on a drug test, it needs to be studied in the lab.
Also read-European Cannabis Regulators Ease Restrictions in Preparation of EU Green Wave
Addiction from high potency?
New research suggests that The Lancet of Psychiatry published new European research on July 25, 2022. Tom Freeman of the University of Bath and colleagues revealed early evidence that THC potency may be linked to psychosis and cannabis use disorder, an addiction condition. Literature research found a link between milligrams of delta-9 THC potency and psychosis and cannabis use disorder symptoms. This is one of the largest patient data reviews to date. More research reveals a link between the THC level in marijuana products and psychological illnesses.